ESR1 and breast cancer: Therefore, the pleiotropy of CUR makes this substance a potential multi-target drug in breast cancer and even more so in ERα-positive breast cancer, since it has been demonstrated to modulate oncogenic signaling pathways that could reactivate ERα through a mechanism independent of its ligand binding [39].